These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 28737986

  • 1. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D, Nicholas J, Carraro M, Zhou J, Hou Q, Babb J, Riester K, Mendoza JP, Livingston T, Jhaveri M.
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [Abstract] [Full Text] [Related]

  • 3. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC, Conway D, Cox GM, Peeples M, Bensimon AG, Macheca M, Herrera V.
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR, Li J, Hutton GJ, Bentley JP, Aparasu RR.
    Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
    [Abstract] [Full Text] [Related]

  • 6. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [Abstract] [Full Text] [Related]

  • 7. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, Evans C, Tremlett H.
    Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-life use of oral disease-modifying treatments in Austria.
    Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 13. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G.
    J Manag Care Spec Pharm; 2021 May 22; 27(5):639-649. PubMed ID: 33624535
    [Abstract] [Full Text] [Related]

  • 14. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T, Kurzeja A, Muresan B, Haas JS, Alexander J, Driessen MT.
    Neurodegener Dis Manag; 2022 Apr 22; 12(2):93-107. PubMed ID: 34931528
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A.
    Pharmacol Res; 2017 Jun 22; 120():279-293. PubMed ID: 28396093
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P, Suchet L, Colamarino R, Laurendeau C, Detournay B.
    Mult Scler Relat Disord; 2020 Nov 22; 46():102521. PubMed ID: 32977077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.